Related Experiment Video
Updated: Jun 1, 2026
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
Published on: July 5, 2021
MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy
Kazuna Takeda1, Shotaro Kanao, Tomohisa Okada
1Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawaharacho, Sakyoku, Kyoto 606-8507, Japan.
Aim:
To investigate if there is any difference in evaluation of residual tumor size after neoadjuvant chemotherapy (NAC) and neoadjuvant endocrine therapy (NAE).
Methods:
Seventy-eight tumors in 57 patients were prospectively enrolled. Residual tumor sizes in contrast-enhanced MRI after NAC and NAE were compared with those measured on surgical specimen by using linear regression analyses. The line slope values >1 indicates overestimation by MRI. Differences in types of shrinkage patterns: concentric shrinkage (CS) and dendritic shrinkage (DS) were also investigated.
Results:
Fifty lesions were treated with NAC and 28 lesions were treated with NAE. Shrinkage patterns were CS in 33 lesions and in 45 lesions. The slopes values were 0.75 (R=0.92) and 0.70 (R=0.90) for NAC and NAE, respectively, and no significant difference was observed (p=0.46). However, they were 1.02 (R=0.92) and 0.68 (R=0.92), respectively for CS and DS with significant difference (p<0.01). The difference between CS and DS was found only in a subgroup with size by MRI >20 mm.
Conclusion:
Contrast enhanced MRI enabled fairly accurate measurement in NAE as well as in NAC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:13Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022